• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[组织型纤溶酶原激活物及其在前列腺癌手术患者血液中的抑制作用]

[Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].

作者信息

Iwan-Zietek I, Zietek Z, Kotschy M, Rość D, Tyloch F

机构信息

Katedry i Zakładu Patofizjologii, Katedry i Kliniki Urologii Akademii Medycznej, Bydgoszczy.

出版信息

Pol Tyg Lek. 1996 Feb;51(6-9):91-3.

PMID:8756741
Abstract

In 30 patients with prostatic carcinoma a higher of t-PA, a low of PAI-1, alpha 2-antiplasmin and plasminogen activity with increased fibrin degradation products (FDP) level and a short euglobulin lysis time (ELT) were observed. Following surgery a further increased of fibrinolytic activity occurred. The activity of t-PA and PAI-1 were higher than before operation. Apart from that we observed a decreased of plasminogen and alpha 2-AP with further increased level of FDP. On 5-th day the values of examined parameters were similar as before the operation.

摘要

在30例前列腺癌患者中,观察到组织型纤溶酶原激活物(t-PA)水平较高、纤溶酶原激活物抑制剂-1(PAI-1)、α2-抗纤溶酶和纤溶酶原活性较低,纤维蛋白降解产物(FDP)水平升高,优球蛋白溶解时间(ELT)缩短。手术后纤溶活性进一步增强。t-PA和PAI-1的活性高于手术前。除此之外,我们观察到纤溶酶原和α2-抗纤溶酶减少,FDP水平进一步升高。在第5天,检测参数的值与手术前相似。

相似文献

1
[Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].[组织型纤溶酶原激活物及其在前列腺癌手术患者血液中的抑制作用]
Pol Tyg Lek. 1996 Feb;51(6-9):91-3.
2
Fibrinolysis system in patients with bronchial asthma.支气管哮喘患者的纤溶系统
Med Sci Monit. 2000 Jan-Feb;6(1):103-7.
3
Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.某些骨髓增殖性综合征中的纤溶酶原激活剂(组织型纤溶酶原激活剂和尿激酶型纤溶酶原激活剂)及纤溶酶原激活剂抑制剂(PAI - 1和PAI - 2)
Med Sci Monit. 2000 Jul-Aug;6(4):684-91.
4
[Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].[闭塞性动脉粥样硬化症和糖尿病大血管病变患者的纤溶酶原激活剂(组织型纤溶酶原激活剂和尿激酶型纤溶酶原激活剂)及其他纤溶参数]
Pol Merkur Lekarski. 2001 Nov;11(65):414-7.
5
Enhanced fibrinolytic activity during the course of hemodialysis.血液透析过程中纤溶活性增强。
Clin Nephrol. 1992 Aug;38(2):90-6.
6
In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.体外凝块溶解作为血栓对纤维蛋白溶解抵抗的潜在指标——在健康受试者中的研究及其与血液纤溶参数的相关性
Thromb Haemost. 1997 Apr;77(4):725-9.
7
Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.严重创伤后血浆中纤溶激活剂和抑制剂的水平
Blood Coagul Fibrinolysis. 1994 Feb;5(1):43-9.
8
Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.血管紧张素转换酶抑制对需要冠状动脉搭桥术患者纤溶系统的影响。
Thorac Cardiovasc Surg. 2009 Sep;57(6):368-71. doi: 10.1055/s-0029-1185596. Epub 2009 Aug 25.
9
[Tissue plasminogen activator, its inhibitor and other parameters of fibrinolysis in blood of patients operated for mild hypertrophy of the prostate].[组织型纤溶酶原激活剂、其抑制剂及轻度前列腺增生手术患者血液中其他纤溶参数]
Pol Tyg Lek. 1992;47(49-50):1096-7.
10
Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.与低纤溶酶原激活物抑制剂1活性相关的高纤维蛋白溶解的实验室证据。
Blood Coagul Fibrinolysis. 2007 Oct;18(7):657-60. doi: 10.1097/MBC.0b013e3282dded21.